A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor
A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor
To assess the clinical effective dose of KRN321 administered with once triweekly schedule.
Inclusion Criteria:

 -  patients diagnosed as solid tumor or malignant lymphoma

 -  patients receiving cyclic chemotherapy

 -  written informed consent

 -  hemoglobin concentration below 11 d/dL at enrollment

 -  life expectancy of more than 4 months

 Exclusion Criteria:

 -  hemolysis, gastrointestinal bleeding, postoperative bleeding

 -  iron deficiency

 -  megaloblastic anemia

 -  received > 2 RBC transfusions within 4 weeks before randomization or any RBC
 transfusion within 2 weeks before randomization

 -  any primary hematological disorder that could cause anemia

 -  prior treatment with KRN321

 -  received erythropoetin therapy within 8 weeks before treatment